Short-term overexpression of VEGF-A in mouse beta cells indirectly stimulates their proliferation and protects against diabetes

  • Nico De Leu
  • , Yves Heremans
  • , Violette Coppens
  • , Naomi Van Gassen
  • , Ying Cai
  • , Joke D'Hoker
  • , Judith Magenheim
  • , Seth Salpeter
  • , Avital Swisa
  • , Abed Khalaileh
  • , Carole Arnold
  • , Gerard Gradwohl
  • , Mark Van De Casteele
  • , Eli Keshet
  • , Yuval Dor
  • , Harry Heimberg*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Aims/hypothesis: Vascular endothelial growth factor (VEGF) has been recognised by loss-of-function experiments as a pleiotropic factor with importance in embryonic pancreas development and postnatal beta cell function. Chronic, non-conditional overexpression of VEGF-A has a deleterious effect on beta cell development and function. We report, for the first time, a conditional gain-of-function study to evaluate the effect of transient VEGF-A overexpression by adult pancreatic beta cells on islet vasculature and beta cell proliferation and survival, under both normal physiological and injury conditions. Methods: In a transgenic mouse strain, overexpressing VEGF-A in a doxycycline-inducible and beta cell-specific manner, we evaluated the ability of VEGF-A to affect islet vessel density, beta cell proliferation and protection of the adult beta cell mass from toxin-induced injury. Results: Short-term VEGF-A overexpression resulted in islet hypervascularisation, increased beta cell proliferation and protection from toxin-mediated beta cell death, and thereby prevented the development of hyperglycaemia. Extended overexpression of VEGF-A led to impaired glucose tolerance, elevated fasting glycaemia and a decreased beta cell mass. Conclusions/interpretation: Overexpression of VEGF-A in beta cells time-dependently affects glycometabolic control and beta cell protection and proliferation. These data nourish further studies to examine the role of controlled VEGF delivery in (pre)clinical applications aimed at protecting and/or restoring the injured beta cell mass.

Original languageEnglish
Pages (from-to)140-147
Number of pages8
JournalDiabetologia
Volume57
Issue number1
DOIs
StatePublished - Jan 2014

Bibliographical note

Funding Information:
Funding Financial support was from the Beta Cell Biology Consortium (CBP, BRAVE) (YD, HH), from the European Union (6th and 7th framework programme ‘BETACELLTHERAPY’) (YD, HH), from the Research Foundation - Flanders (FWO) (fellowship to NDL) and from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) (fellowships to JDH, VC and NVG).

Keywords

  • Beta cell proliferation
  • Beta cell protection
  • VEGF

Fingerprint

Dive into the research topics of 'Short-term overexpression of VEGF-A in mouse beta cells indirectly stimulates their proliferation and protects against diabetes'. Together they form a unique fingerprint.

Cite this